Bio­science in­dus­try stake­hold­er col­lab­o­ra­tion key to ad­dress­ing in­equal­i­ty

Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.

When a glob­al pan­dem­ic hit, the bio­science in­dus­try an­swered the call for vac­cines and ther­a­pies in record time, which will save mil­lions of lives. This re­sponse was pos­si­ble be­cause of a sus­tained in­vest­ment of risk-cap­i­tal by the ven­ture cap­i­tal in­dus­try in life sci­ences com­pa­nies, peak­ing in 2020. Great sci­en­tists, vi­sion­ary lead­er­ship and high-qual­i­ty in­vestors that backed new sci­ence and bold en­tre­pre­neurs led to the in­no­v­a­tive tech­nolo­gies of BioN­Tech and Mod­er­na that con­tributed to the ini­tial Covid-19 vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER